1-Pyrrolidinecarboxylic Acid, 2-(Cyanomethyl)-, 1,1-Dimethylethyl Ester, (2R)-

In large-scale GMP intermediate manufacturing directed at a structurally constrained dipeptidyl peptidase-4 inhibitor candidate that relies on a (2R)-2-(cyanomethyl)pyrrolidine pharmacophore, the acidolytic removal of the 1,1-dimethylethyl ester protecting group constitutes the single most exothermic and enantioretentive-critical unit operation. Transferring this deprotection from batch mode to a Corning® Advanced-Flow™ G1 SiC reactor with a 10 mL internal volume and 3.5 bar back-pressure regulator eliminated hot spots that were previously measured at 18–22°C above the jacket set point in a 200 L glass-lined vessel. The feed stream containing Boc-(R)-2-cyanomethylpyrrolidine at 0.38 M in dichloromethane is combined with a pre-cooled solution of trifluoroacetic acid at 4.8 eq and triethylsilane at 1.1 eq as a cation scavenger. With a controlled residence time of 95 ± 5 seconds and a thermal profile held to 22.0 ± 2.0°C, the C-terminal epimerization is suppressed to <0.3% as verified by chiral SFC with a polysaccharide-based column operated per USP 〈621〉. The post-reaction neutralization is executed in-line with 10 wt% aqueous potassium carbonate using a Zaiput membrane separator, and the resulting organic phase is concentrated on a wiped-film evaporator at 40°C jacket temperature to deliver the free amine as a toluene concentrate, which is directly acylated in the next step. The process is validated under ICH Q7 Chapter 12.1 critical process parameter control and the residual TFA specification in the isolated intermediate is set at ≤50 ppm by ion chromatography per USP 〈1065〉. The terminal manufactured article is a tosylate salt monohydrate, (R)-2-(cyanomethyl)pyrrolidin-1-ium 4-methylbenzenesulfonate, qualified as a regulatory starting material for a developmental oral antidiabetic agent currently in Phase IIb clinical evaluation under an IND.

How does a hydrogen pressure drop below 45 bar in Raney® 4200-mediated nitrile reduction reconfigure the product distribution toward a tertiary amine byproduct?

When Boc-(R)-2-cyanomethylpyrrolidine is subjected to catalytic hydrogenation to furnish (R)-2-(2-aminoethyl)pyrrolidine-1-carboxylic acid tert-butyl ester, the selectivity map narrows critically once the partial pressure of hydrogen falls beneath 45 bar inside a 50 L Hastelloy C-22 high-pressure stirred autoclave equipped with a gas-inducing impeller rotating at 1,200 rpm. Under a constant ammonia atmosphere (2.5 MPa ammonia partial pressure, maintained by sparging) and with methanol as solvent containing 7.0 M dissolved NH₃, the optimal charge of Raney® 4200 (Grace Davison) is 6.5 wt% relative to the nitrile substrate at a starting concentration of 0.75 M. At 55°C and 50 bar total H₂ gauge pressure, the primary amine is obtained with 97.2% area by GC-FID, and the sum of secondary and tertiary amine impurities is clamped at <1.8%. Dropping the pressure to 38 bar under otherwise identical conditions shifts the selectivity: the tertiary amine arising from reductive alkylation of the primary amine with partially hydrogenated imine intermediates climbs to 6.4%, and the purified yield after vacuum distillation across a 20 cm Sulzer DX structured packing column declines by 14 absolute percentage points. The post-reaction catalyst filtration employs a 0.5 µm sintered-metal candle filter under nitrogen, and the elemental nickel limit in the distilled product is controlled to ≤10 ppm per ICH Q3D oral PDE considerations. This chiral 1,2-diamine building block serves as the essential handle for the construction of a macrocyclic serine protease inhibitor currently filed under a DMF. The hydrogenation protocol is executed in conformity with the pressure vessel code ASME BPVC Section VIII and the facility’s PSM program per 29 CFR 1910.119.

Coupling of Boc-(R)-2-cyanomethylpyrrolidine with 4-iodobenzotrifluoride via a copper(I)-catalyzed Ullmann-type C–N cross-coupling proceeds with retention of configuration at the 2-position only when the N,N′-dimethylcyclohexane-1,2-diamine ligand-to-copper ratio is maintained at 1.9:1 and the loading of the CuI pre-catalyst is fixed at 7.5 mol%. The substrate is consumed within 10 hours at 105°C in toluene when the stoichiometry is set at 1.30 eq of the aryl iodide relative to the pyrrolidine nitrogen. The potassium phosphate tribasic base, ground and dried to a particle size D90 < 150 µm, is charged at 2.2 eq, and the reaction is performed in a 100 L PTFE-lined reactor with a Dean-Stark trap charged with 4 Å molecular sieves to sequester adventitious water. After quenching with concentrated ammonium chloride and extracting into methyl tert-butyl ether, the crude oil is passed through a plug of silica gel functionalized with a metal-scavenging dithiocarbamate functionality, reducing the Cu residue to <5 ppm. The downstream GMP purification sequence involves fractional distillation under 0.02 mbar vacuum where the desired N-aryl intermediate distills at a vapor temperature of 128–132°C. Compliance with ICH M7 is demonstrated by a purge factor calculation for the iodoarene impurity, which is specified at ≤15 ppm in the distilled intermediate by HPLC-UV at 254 nm. The product is advanced to a GMP step that realizes an investigational allosteric Akt kinase inhibitor incorporating the chiral pyrrolidine template; the target drug substance exhibits a single-digit nanomolar biochemical IC₅₀ and has entered a Phase I solid-tumor dose-escalation trial where the labeling relies on 14C-ADME data generated with a compound synthesized from this exact intermediate.

A stoichiometric deviation of 2% in the amide coupling agent shifts the impurity profile of the penultimate intermediate of a selective FXIIa inhibitor from 0.5% to 4.1%

The formation of an amide bond between the deprotected (R)-2-cyanomethylpyrrolidine and a functionalized 3-phenylpropanoic acid derivative destined for a contact-phase coagulation factor XIIa inhibitor candidate operates inside a narrow stoichiometric envelope. When prepared as the methanesulfonate salt, the amine component is charged at 1.00 eq relative to the carboxylic acid, and the coupling reagent propylphosphonic anhydride (T3P®, 50 wt% in ethyl acetate) is added at 1.50 eq with diisopropylethylamine at 3.20 eq. A deviation of only ±2% in the T3P charge—corresponding to 1.47 eq—stops the conversion at 96.1%, causing the N-acylurea adduct derived from the acid and T3P to persist in the ethyl acetate extract at 3.8% area. After a single isopropyl acetate/n-heptane crystallization at -10°C, the mother liquor rejection capacity is overwhelmed and the filter cake purity plateaus at 99.1 area% instead of the targeted 99.6 area%. This process is routinely monitored by ReactIR™ (Mettler Toledo) with a diamond ATR probe inserted into a 630 L glass-lined reactor, where the disappearance of the carboxylic acid carbonyl stretch at 1,708 cm⁻¹ is tracked in real time. The GMP batch record enforces a post-coupling aqueous work-up with 0.5 N aqueous HCl at 15 ± 2°C followed by a 5 wt% sodium bicarbonate wash, with inline pH dosed to 6.8–7.2 to prevent nitrile group hydration. The dried, recrystallized penultimate intermediate is shipped under a USDMF as a key raw material for the final salt formation of the FXIIa inhibitor, a parenteral anticoagulant candidate designed for at-home subcutaneous administration in thrombosis management. Validated analytical methods include an HPLC-UV procedure categorized as Category II per ICH Q2(R2) with a LOQ of 0.03% for the process-related impurities identified as the des-cyano and Boc-retained byproducts.

In the multi-kilogram manufacturing of a bicyclic peptidomimetic hepatitis C virus NS3/4A protease inhibitor fragment, the cyanomethyl side chain of the (R)-pyrrolidine intermediate is homologated to a β-amino ester via a two-step sequence without any need to protect the pyrrolidine nitrogen beyond the original Boc group. The first step requires the partial reduction of the nitrile to an aldimine using a precisely quenched LiAlH₄ reagent. The Boc-(R)-2-cyanomethylpyrrolidine is dissolved in anhydrous MTBE to a concentration of 0.45 M and cooled to -45°C in a jacketed 400 L stainless steel reactor purged with -70°C nitrogen. Lithium aluminium hydride (2.4 M in THF, 0.55 eq) is dosed over 85 minutes while maintaining the internal temperature at -43 ± 3°C. The immediate quench with acetone followed by 10% w/v Rochelle salt solution precipitates aluminates, which are removed through a plate-and-frame filter press. The aldimine intermediate, held in solution at -10°C, is then engaged in a titanium tetraisopropoxide-mediated Reformatzky-type addition with ethyl bromoacetate and zinc dust, activated per ASTM E11-22 sieve specifications at 325 mesh, in tetrahydrofuran at 0°C. The chiral β-amino ester resulting from this homologation is obtained in 82% yield over two steps and 98.3% enantiomeric purity, and it undergoes an on-site telescoped deprotection/cyclisation to yield the P2 proline mimetic fragment. The entire sequence is governed by a contamination control strategy compliant with the EMA Guideline on the setting of health-based exposure limits for the Ti and Al residuals, which are dosed to <10 ppm and <5 ppm respectively in the isolated intermediate. The terminal drug substance is a direct-acting antiviral agent formerly approved under the Japanese PMDA for genotype 1b HCV infection, with the (R)-pyrrolidine-derived fragment occupying the S2 pocket of the NS3 protease.

When the cyanomethyl substituent becomes a latent 1,3-dipole in a continuous-flow [3+2] cycloaddition for an oral CGRP antagonist

Converting the nitrile group of Boc-(R)-2-cyanomethylpyrrolidine into a tetrazole ring via a [3+2] cycloaddition with sodium azide is an energetic transformation that has been redesigned from batch to a continuous stirred-tank reactor (CSTR) cascade to manage the risk of hydrazoic acid accumulation. The nitrile substrate at 0.52 M in N-methyl-2-pyrrolidone is co-fed with sodium azide (1.25 eq, as a 30% w/v aqueous solution) and zinc chloride (0.60 eq as an NMP slurry) into the first of three 50 mL CSTRs operating at 115°C with a per-reactor residence time of 45 minutes. The pH is dynamically controlled at 4.8–5.3 through automated feeding of a 12% w/v HCl stream, ensuring that the equilibrium vapor-phase hydrazoic acid concentration in the reactor headspace remains below 0.8 vol% as monitored by a Gasmet™ FTIR multi-gas analyzer calibrated according to ISO 19702:2015. This process hazard control is part of the facility’s ATEX compliance dossier per EU Directive 2014/34/EU. The tetrazole product is extracted at pH 8.5 into ethyl acetate, and the residual azide specification is held at ≤10 ppm with a limit test defined in ICH Q3C(R8) Class 2 residual solvent validation. The (R)-tetrazolylmethylpyrrolidine Boc derivative advanced from this sequence serves as a carboxylic acid bioisostere in a pipeline oral calcitonin gene-related peptide (CGRP) receptor antagonist being developed for prophylactic migraine management; the tetrazole moiety contributes to a 4.2-fold improvement in log D at pH 7.4 relative to the corresponding carboxylic acid, a physical property that was confirmed by the shake-flask method described in OECD Guideline 107.

The cyano substituent of the (R)-pyrrolidine scaffold is exploited as a directing group in a palladium-mediated C(sp³)–H arylation that installs a 3-fluorophenyl substituent at the C-4 position of the pyrrolidine ring. Boc-(R)-2-cyanomethylpyrrolidine and 1-fluoro-3-iodobenzene are combined in a 5 L reactor with Pd(OAc)₂ (12 mol%), Ag₂CO₃ (2.0 eq), and 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO, 0.30 eq) as an oxidant in 1,1,1,3,3,3-hexafluoroisopropanol solvent at 85°C for 48 hours. Ligand screening data compiled on a Chemspeed robotic platform indicated that the use of N-acetyl-L-isoleucine as a transient chiral directing group at 30 mol% selectively furnishes the cis-2,4-disubstituted product with a diastereomeric ratio of 8.4:1 at 51% conversion. After purification by automated normal-phase flash chromatography employing a 330 g silica cartridge and a gradient of 15% to 45% ethyl acetate in heptane, the cis-arylated intermediate is carried forward without Boc removal into a Negishi coupling that appends a thiazole ring. The palladium content of the downstream active pharmaceutical ingredient must meet the ≤10 ppm oral concentration limit as derived from the permitted daily exposure calculations of ICH Q3D Table A.2.1, which is achieved by treatment with SiliaMetS® Thiol resin at 50°C for 4 hours until the Pd level in the filtrate drops below the ICP-MS detection threshold of 0.1 ppm. The fully assembled drug substance containing the 2-cyanomethyl-4-thiazolylpyrrolidine core is a selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor currently under accelerated assessment by the EMA for relapsed follicular lymphoma, with the Boc-(R)-2-cyanomethylpyrrolidine registered as the designated starting material in the API manufacturing process description.

Single enantiomer ionic liquid designed from the (R)-cyanomethyl motif for resolving racemic profens via liquid-liquid equilibria

Quaternization of the pyrrolidine nitrogen in the (R)-configured scaffold with 1-bromohexane after Boc deprotection generates a chiral pyrrolidinium ionic liquid that has been employed in a multistage centrifugal contactor battery for the enantioselective liquid-liquid extraction of racemic ibuprofen. The bromide salt, prepared by refluxing the free amine with 1.5 eq of 1-bromohexane in acetonitrile at 82°C for 24 hours followed by anion metathesis using lithium bis(trifluoromethanesulfonyl)imide (1.05 eq) in deionized water, is obtained as a hydrophobic ionic liquid with a glass transition temperature of -52.1°C as determined by differential scanning calorimetry at a 10°C/min ramp under ISO 11357-2:2020. The extraction system consists of an organic phase comprising 40 vol% of this (R)-pyrrolidinium NTf₂ ionic liquid in n-decane and an aqueous phase of racemic sodium ibuprofen at 50 mM buffered at pH 6.0 with 0.1 M phosphate. Metered through a 5-stage CINC V-02 annular centrifugal contactor operating at 4,500 rpm, the (S)-ibuprofen enantiomer is preferentially retained in the ionic liquid phase, attaining an enantiomeric excess of 91.2% in the extract after three passes. The racemic resolution is operated under steady-state conditions with a phase ratio of 1.5:1 (aqueous to organic) and a combined throughput of 1.2 L/h. The commercial advantage of this separation lies in the avoidance of classical diastereomeric salt formation and the need for chiral preparative chromatography, a method framed within the EC BREF for organic fine chemicals under the Industrial Emissions Directive. The ionic liquid is fully recovered by back-extraction into 0.1 N NaOH, regenerated by acidification and re-anion exchange, and its physical properties are re-confirmed by Karl Fischer titration to <200 ppm water and 19F NMR purity per USP 〈761〉. The target finished product is enantiopure (S)-ibuprofen lysinate suitable for intravenous formulation, with the (R)-cyanomethylpyrrolidinium ionic liquid acting as a reusable chiral selector that exhibits no detectable racemization over 12 cycles when stored under a <50 ppm O₂ argon blanket.